<![CDATA[Olomorasib Earns FDA Breakthrough Therapy in KRAS G12C+ Pancreatic Cancer]]>
RegulatorypositiveolomorasibPositive
AI Analysis
Summary
The FDA has granted breakthrough therapy designation to olomorasib for previously treated, KRAS G12C-mutant advanced pancreatic cancer, recognizing the drug's potential therapeutic advantage in this indication.
Outcome Details
FDA granted breakthrough therapy designation
Importance:8/10
Sentiment:
0.85
FDABreakthrough Therapy DesignationKRAS G12CPancreatic CancerOncology
Read the original article
Published by Cancer Network on August 4, 2026 3:30 PM